Lipids for use in lipid nanoparticle formulations
OwnerJason Samuel Tan, Stephen Paul Arns +1inventors
InventorsJason Samuel Tan, Stephen Paul Arns, Julia Gatenyo
Life of this patent
Estimating the term…
Abstract
Compounds are provided having the following Structure (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R1, L1, L2, L2a, L2b, and A are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Claims38
A compound having the following structure (I):
- or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
- A is a 3-10 membered carbocyclic or oxygen-containing heterocyclic ring optionally substituted with one or more fluoro, hydroxyl, C1-C6 alkyl, or C1-C6 alkylhydroxyl substituents;
- R1 is —NRaC(═O)R3 or —C(═O)NRbRc;
- R2 is —NRdC(═O)R4 or —C(═O)NReRf;
- R3 and R4 are each independently C6-C24 alkyl or C6-C24 alkenyl;
- Ra, Rb, Rd and Re are each independently H, C1-C20 alkyl or C2-C20 alkenyl;
- Re and Rf are each independently C1-C20 alkyl or C2-C20 alkenyl;
- L1 and L2 are each independently a direct bond or C1-C6 alkylene;
- and
- L2a and L2b are each independently C4-C12 alkylene;
- wherein each alkyl, alkylene, and alkenyl is optionally substituted with one or more fluoro.
5-6. (canceled)
8-9. (canceled)
11-12. (canceled)
14-15. (canceled)
(canceled)
21-22. (canceled)
24-29. (canceled)
(canceled)
(canceled)
39-40. (canceled)
42-45. (canceled)
47-49. (canceled)
54-56. (canceled)
Dependencies are inferred from the claim text.